Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks. (September 2016) - Farnier, M.; Colhoun, H.M.; Sasiela, W.J.; Edelberg, J.; Asset, G.; Robinson, J.G.